Panevezio Statybos Lt 1 Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Panevezio Statybos Lt 1 in the next few years
Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Panevezio Statybos Lt 1 vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Panevezio Statybos Lt 1 | - | - | - | - | - | - | - |
| J+p-Avax S.a. Nam. Eo 0,58 | 0.000% | 7.798% | 4.599% | 67.857% | 60.959% | 186.585% | 333.047% |
| Verbrec Ltd. | 0.000% | 0.962% | 1.942% | 130.769% | -7.895% | 141.379% | 28.049% |
| Inypsa | -1.930% | 0.000% | -1.308% | -21.252% | -1.190% | -45.215% | 2.469% |
News
Bicara Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Bicara Therapeutics Inc.? Here are five stocks we like better.
- FICERA’s pivotal FORTIFI-HN01 trial remains on track for substantial enrollment by the end of 2026, with
KORU Medical Systems Q2 Earnings Call Highlights
Key Points
- Interested in KORU Medical Systems, Inc.? Here are five stocks we like better.
- Second-quarter revenue rose 18% to $12 million, driven by domestic patient starts, market-share gains
Ingersoll Rand Q2 Earnings Call Highlights
Key Points
- Interested in Ingersoll Rand Inc.? Here are five stocks we like better.
- Ingersoll Rand reported solid Q2 growth: Organic revenue rose 4%, organic orders increased 2%, and adjusted EPS